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A minor population of murine B iymphocytes express the cell surface antigen 
Ly-1 (1), and a similarly small proportion of human B cells carry the homologous 
antigen  Leu-1/T1  (2).  In normal  mice, ~2-5% of splenic B cells bear Ly-1, but 
these include virtually all of the cells that spontaneously secrete antibody hemo- 
lytic for SRBC or for autologous erythrocytes treated with the proteolytic enzyme 
bromelain  (BrMRBC). 1 In  NZB  mice,  which  develop  congenital  autoimmune 
disease, the frequency of Ly-1 + B cells is elevated (3),  and they are reportedly 
responsible for the production of all the anti-DNA antibodies associated with the 
disease (4). 
We  have  previously  described  (5)  27  independently  derived  murine  B  cell 
lymphomas in the CH series. At least 70% of these tumors bear Ly-1, their  Ig 
are  idiotypicaily related  one to another,  and  several recognize  SRBC and  Br- 
MRBC via their  surface Ig (5).  The  spleens of normal  syngeneic mice contain 
Ly-1 + B cells that produce antibody hemolytic for SRBC and BrMRBC. About 
half of these cells are idiotypically crossreactive with the erythrocyte-reactive CH 
lymphomas (6). This implies that the CH lymphomas represent neoplastic analogs 
of the Ly-1 + normal B cells. 
During an experiment  using antibody-conjugated, dye-loaded liposomes as a 
second-step immunofluorescence reagent, we noted that CH 12 tumor cells bound 
them  independently  of the  addition  of first-step  antibody.  Binding  was not  a 
function  of the  specificity of the  antibody  conjugated  to  the  liposomes,  but 
occurred with all liposomes of similar phospholipid composition. Given that the 
liposomes are constructed with phospholipids similar to those present in eryth- 
rocyte membranes and that some erythrocytes bind to members of the CH series 
by way of surface  IgM  (sIgM),  we decided  to  explore  the  possibility that  the 
particular  epitope recognized by CH 12 Ig was included as a  component of the 
fluorescent dye-loaded liposomes. 
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phatidyl glycerol; GARb, goat antiserum to rabbit lg. 
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After showing that liposome attachment to CH 12 cells was due to binding to 
sIgM, we tested a panel of other CH tumor cells for their ability to bind liposomes. 
We report here that all six of the CH lymphomas that bear sIgM reactive with 
both SRBC and BrMRBC also bind our tracer liposomes. Experiments involving 
blocking of liposome binding on the cell surface and a competition immunoassay 
have  enabled  us  to  show  that  the  epitope  recognized by these  tumors  is  the 
phosphatidyl choline moiety of membrane phospholipids. We also discuss signif- 
icance of this finding in relation to other commonly studied autoantigens and to 
the restricted specificity of normal Ly-1 ÷ B cells. 
Materials and Methods 
Mice and Tumors.  BlO.H-2~H-4bp/Wts (2a4  b) were bred and maintained in our patho- 
gen-free mouse colony. This strain had been derived from selected F2 progeny of B10.A 
a  b  X B10.129(21M) mice (7). The CH series of B cell lymphomas arose in 2 4  mice following 
adoptive hyperimmunization with SRBC. Details concerning the induction of CH 1-CH 12 
have been reported by Lanier et al. (8), and Pennell et al. (5) have reported on CH15- 
CH39. The tumors were maintained by serial transplantation of ascites or splenic tissue 
in syngeneic animals, or in tissue culture in RPMI  1640 supplemented with  10%  FCS, 
glutamine, gentamycin and 2-ME. 
Liposomes.  Fluorescein-encapsulating,  Ig-conjugated  liposomes were  prepared  by a 
modification of the reverse-phase evaporation method of Szoka and Papahadjapoulos (9). 
Briefly, 119 #moles distearoylphosphatidyl choline (DSPC) (Avanti Polar Lipids, Birming- 
ham, AL), 13.2 #moles distearoylphosphatidyl glycerol (DSPG) (Avanti Polar Lipids), 3.75 
#moles of a maleimido derivative of distearoyl phosphatidyl ethanolamine (girl of Dr J. P. 
O'Connell, Becton Dickinson Research Center, Research Triangle Park, NC) and  132 
#moles of cholesterol (Sigma Chemical Co., St. Louis, MO) were dissolved in 6:1 chloro- 
form/methanol. This lipid solution was emulsified by sonication with 2/7 volume of 5 
mM  6-carboxyfluorescein (Eastman  Kodak,  Rochester, NY) in an  isotonic TrisoEDTA 
buffer, pH 5.5. Organic solvent was then removed by rotary evaporation. This preparation 
was warmed above the transition temperature, then extruded through 0.4- and 0.2-#m 
filters in the presence of an additional five volumes of dye solution. Unencapsulated dye 
was washed away by ultracentrifugation. Affinity-purified goat anti-rabbit Ig, heavy and 
light chain-specific (Cappel Laboratories, Cochranville, MD) or human IgG (Miles Pentex, 
Los Angeles, CA) were reduced with DTT. Reduced antibodies were allowed to react 
with  prepared  liposomes overnight at  room  temperature.  Unconjugated  protein  was 
washed away by ultracentrifugation. 
Liposomes used in the solid-phase IgM-mediated binding assay were the kind gift of 
Dan McLaurin (Becton-Dickinson Research Center). Their lipid formulation was identical 
with that of  the carboxyfluorescein  liposomes described above. These vesicles encapsulated 
sulforhodamine-B and had no protein conjugated. Stock suspensions of both dye-loaded 
liposomes were adjusted to ~2 mM in inorganic phosphate as determined by the method 
of Fiske and SubbfiRow (10). 
Empty vesicles used in CH-lymphoma blocking experiments were prepared by drying 
34 #moles DSPC or DSPG plus 33 #moles cholesterol to a thin film on a round-bottom 
flask.  Lipids were then dispersed in PBS above the transition temperature and extruded 
through a 0.2 ~m filter. 
Liposome Binding to CH-Lymphoma  Cells.  An equal volume of  cell suspension, containing 
107 viable cells/ml in HBSS plus 0.1% BSA was incubated with a  1:10 dilution of empty 
DSPC- or DSPG-vesicles,  or medium only, for 1 h at 37°C (capping conditions), or for 20 
min on ice in the presence of NaN3 (blocking conditions). Cells were washed twice with 
HBSS/BSA/NaN3, then resuspended to the original volume. Aliquots (100 #1) of tumor 
cells were  then  incubated  with  25  #1  of rabbit  anti-mouse  #-chain  antibody  (Litton 
Bionetics, Kensington, MD) at a 1:4 dilution, for 30 min on ice. Controls were 1:4 dilutions 
of normal rabbit serum or buffer alone. Three washes  with HBSS followed. Liposomes MERCOLINO  ET  AL.  157 
conjugated with goat anti-rabbit lg were added (50 #1 of a  1:10 dilution) and incubated 
on ice for 30 min. Cells were then washed three times with PBS plus NAN3. Analysis was 
performed on an EPICS V cell sorter (Coulter Electronics, Hialeah, FL) using the 488 
nm line from an argon-ion laser. Cells that did not bind liposomes directly were examined 
for  indirect  binding  mediated  by  the  rabbit  anti-#  antibody  and  the  anti-rabbit  Ig 
specificity of the liposomes. 
Quantitation of Cell Surface IgM.  Surface IgM of CH-iymphomas was determined by 
indirect immunofluorescence. 100 #1 of tumor cells at 107 ceils/ml were incubated for 20 
min on ice with rat mAb specific for mouse IgM (clone 331.12,  [11]) or no antibody as 
control, washed twice with HBSS]NaN3, then stained with fluoresceinated mouse anti- 
rat  K chain  mAb  (MAR18.5,  Becton  Dickinson  Immunocytometry Systems,  Mountain 
View, CA).  After three washes with PBS]NaNs, cells were resuspended to  106 cells/ml 
and analyzed on the EPICS V as described above. 
Liposome Agglutination.  A hybridoma was prepared by fusing CH12 lymphoma cells 
with the P3-X63-Ag8.653 nonsecreting myeloma cell line as described (5). Agglutination 
was performed by using 15 ~1 of supernatants from CH 12 hybridoma cells, or 25 ~1 of a 
hybridoma  supernatant  with  an  irrelevant  antigen  specificity  (H013.4,  anti-Thy-l.2, 
[ 12]) grown in the same medium. 25 ~1 of human IgG-conjugated, fluorescein-containing 
liposomes were then mixed with the antibodies on a glass slide with a black background. 
After 60 min at room temprature, results were visualized using a  hand-held ultraviolet 
lamp. 
IgM-mediated Liposome Binding to Polyacrylamide Beads.  One vial of goat anti-rabbit Ig 
polyacrylamide beads (Immunobead Second Antibody; Bio-Rad Laboratories, Richmond, 
CA) at 4 mg/ml in 150 mM EDTA, pH 7.5, with 0.1% dextran (assay buffer) was reacted 
for 5 min at 37°C with  16 ml of a  1:50 dilution of affinity-purified rabbit anti-mouse 
chain antibody (Jackson Immunoresearch Laboratories, Bar Harbor, ME),  then washed 
three  times with  assay buffer.  The pellet was then  resuspended  to the original  50-ml 
volume, and 25 ml reacted with 8 ml of a 1:10 dilution of the IgM-containing supernatant 
of the C H 12 hybridoma (concentrated 10-fold by addition of saturated ammonium sulfate 
concentrate). An additional  10 ml of anti-mouse ~-specific beads was reacted with 3.2 ml 
of a 1:10 dilution of CH 10 hybridoma supernatant. After 5 min at 37 o  C, both preparations 
were washed three times with assay buffer. 
Blocking of the IgM-mediated liposome binding to the polyacrylamide beads was then 
attempted. Inhibitor phospholipid suspensions were prepared by drying under a stream 
of nitrogen, 1 ml of a 20 mg/ml solution of DSPC (Sigma Chemical Co.), sphingomyelin 
(Sigma Chemical Co.), or DSPG (Avanti Polar Lipids) in chloroform to the wall of a clean 
glass scintillation vial. The dry lipid film was then dispersed in 10 ml of 150 mM EDTA, 
pH 7.5, at 57°C, and extruded at this temperature through a 0.22-#m Millex GV filter 
prewashed with the buffer. 
750  ul of the  incubators,  at 0.5-0.0625  mg/ml input phospholipid,  were incubated 
with 500 #1 CH-IgM bead suspension for 15 min on ice, then 750 ~! of a 1:80 dilution of 
the stock suspension of sulforhodamine-B liposomes was added, and the incubation was 
continued  for an  additional  5  rain.  3  mi of PBS  was then added,  and  the tubes were 
centrifuged.  Solid-phase  bound  liposomes were lysed  with  1%  Triton  X-100,  and  the 
tubes were recentrifuged. Absorbance of the supernatant at 565 nm was then measured. 
Results 
Liposome  Binding.  Cells  from  14  different  CH  [ymphomas were  tested  for 
binding  of the  fluorescent  liposomes described  above.  Six  of the  tumors  bear 
surface IgM with specificity for SRBC and BrMRBC,  and one of these (CH34) 
also binds E.  coll. Two tumors bear  IgM that  recognizes only BrMRBC,  while 
the Ig expressed by two others recognize only E. coli (4).  Data are presented in 
Table  I.  Liposomes were  bound  directly by all six tumors with  the  SRBC  and 
BrMRBC  specificity, but  not  by any of the  others.  Failure  of a  tumor to bind 158  PHOSPHATIDYL  CHOLINE  BINDING  BY  Ly-1 +  B  LYMPHOMAS 
TABLE  I 
Direct Binding of Fluorescent Liposomes and Its Inhibition by Pure 
Compounds 
Cells  Antigens 
bound* 
Binding of liposomes 
(peak fluorescence channel) 
Alone  DSPC  DSPG* 
CH1  E  <1  --  -- 
CH6  --  <1  --  -- 
CH9  B  <1  --  -- 
CH10  E  <1  --  -- 
CH12  S,  B  150  82  150 
CH15  B  <1  --  -- 
CH27  S,  B  188  <1  184 
CH28  S,  B  150  31  150 
CH29  --  <1  --  -- 
CH30  --  <1  --  -- 
CH32  S,  B  144  <1  149 
CH34  S, B, E  211  140  200 
CH35  S,  B  125  <1  120 
CH39  --  <1  --  -- 
*  Antigen-binding specificity of sIgM. E, E. coli  cells; B, bromelain-treated 
mouse erythrocytes; S, sheep erythrocytes (from Pennell et al. [5]). 
* Cells were  stained with  fluorescent  dye-loaded  liposomes with  DSPC, 
DSPG, and cholesterol as membrane  components. Inhibitors were color- 
less  vesicles of  DSPC/cbolesterol  or  DSPG/cholesterol.  Data  are  the 
peak fluorescence channel numbers determined  by flow cytometry using 
a  256-channel,  three-decade  logarithmic scale;  <1,  fluorescence  peak 
not detected on-scale; --,  test not applicable. 
liposomes directly was not due to absence of slgM, since liposomes conjugated 
with goat anti-rabbit  Ig (GARb) would bind  indirectly after preincubation of 
tumor cells with rabbit anti-mouse IgM sera. We took these data to imply that 
the determinant on  SRBC  and BrMRBC  recognized by CH12,  -27,  -28,  -32, 
-34,  and  -35  was  the  same as,  or similar to  some surface component of our 
synthetic liposomes. As a corollary, the surface component of BrMRBC recog- 
nized by CH9 and -15 must differ from the above epitope and be absent from 
the liposomes. 
We  undertook  blocking  experiments  to  determine  which  of the  liposome 
components carried the epitope  recognized by the six  SRBC-specific  tumors. 
Empty vesicles were prepared with lipid compositions of 50 mol-percents DSPC 
plus 50 mol-percents cholesterol, or 50:50  DSPG/cholesterol. Preincubation of 
tumor cells with DSPC- but not DSPG-containing vesicles reduced the binding 
of fluorescent liposomes from 10-fold (partial blocking) to >l,000-fold (complete 
blocking).  The  relative  degree of blocking  was  the same whether conducted 
under capping or noncapping conditions.  Table  I  also  gives the fluorescence 
intensity  observed  for  the  liposome-binding  CH  lymphomas,  and  results  of 
blocking experiments. Fig. 1 contains sample fluorescence histograms from flow 
cytometric analysis,  which  show  direct  binding  of liposomes  to  CH-tumors, 
blocking by empty vesicles, and use of GARb-conjugated liposomes as second- 
step  reagents  for  indirect  staining  of sIgM  on  CH39.  Data  for  CH27  are MERCOLINO  ET  AL.  159 
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FIGURE  1.  CH27  cells preincubated with RPMI alone (a), empty DSPC/cholesterol liposomes 
(b),  or  empty  DSPG/cholesterol  liposomes  (c),  60  rain,  37°C,  followed  by  staining  with 
DSPC/DSPG/cholesterol  liposomes  encapsulating  carboxyfluorescein  and  conjugated  with 
goat  anti-rabbit  lg  antibody.  CH12  cells  in  d,  e,  and f  treated  as  in  a,  b,  and  c  above, 
respectively. CH39 cells (g) were preincubated as in a  and d above, and serve as an example 
of failure to bind liposornes directly, and as a  control for the indirect liposome immunofluo- 
rescence shown  in  h,  where  cells  were  stained  with  rabbit anti-mouse  #  chain  antibody, 
followed by fluorescent goat anti-rabbit lg liposomes. 
representative of high-density binding  of fluorescent liposomes and  complete 
blocking by preincubation with DSPC-conjugated but not with DSPG-conjugated 
vesicles. CH 12 is an example of lower-density binding and only partial inhibition 
by DSPC. Note (Table I) that a high density of iiposome binding can be associated 
with either complete or partial  blocking by preincubation with DSPC vesicles; 
similarly, tumors that bind liposomes at low density are also blocked by DSPC- 
conjugated vesicles to different extents. Thus, the degree of inhibition is not a 
simple function of the number of iiposomes bound, but is more likely related to 
the avidity of binding. 
These  data  imply  that  the  phosphatidylcboline  moiety  mediates  liposome 
binding to the SRBC rosette-forming CH-lymphomas, and that binding avidity 
differs between tumors. 
Specificity of CH12 IgM for Liposomes.  As a  direct  demonstration that  cell- 
surface Ig was responsible for binding liposomes, we tested the IgM secreted by 
a hybridoma made by fusing CH12 with the nonsecreting myeloma P3-X63 Ag 
8.653. As a control, we used the culture supernatant from H013.4, an anti-Thy- 
1.2 murine IgM, grown under the same conditions. Dilutions of both IgM were 
incubated with  suspensions of the  liposomes used in  the cell-labelling experi- 
ments. Agglutination occurred with CH12  Ig, but not with H013.4 hybridoma 
supernatant (data not shown). 
Correlation of slgM Density with Liposome Binding.  Since the density of lipo- 
somes bound by cells of the various CH tumors differed over a  100-fold range, 
we wanted to know whether this was a function of cell surface concentration of 160  PHOSPHATIDYL  CHOLINE  B1NDING  BY  Ly-1 +  B  LYMPHOMAS 
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FIGURE 2.  Fluorescence  intensity  histograms  of CH12 (a and d), CH34 (b and e), and CH27 
(c and  f) lymphomas  generated by staining  cell populations for surface IgM (a, b, and c) or by 
direct binding of carboxyfluorescein-loaded  liposomes (d, e, and f). Histograms (a-c) were 
collected at a higher sensitivity  than d-f due to the lower fluorescence intensity  of samples 
stained with fluoresceinated  antibodies compared to those stained  with dye-loaded  liposomes; 
data collection  using logarithmic  amplifiers  allows for comparison of intensity  distributions. 
IgM. Indirect immunofluorescence was used to measure the relative concentra- 
tions of sIgM, and this was compound to the density of liposomes bound. The 
log of the peak fluorescence for sIgM and for liposome binding were compared 
by linear regression analysis. A correlation coefficient (r  2) of >0.9 was obtained, 
indicating a  major contribution of the cell-surface IgM concentration to deter- 
mining the degree to which a particular CH lymphoma cell population binds the 
fluorescent liposomes. 
Sample histograms from flow cytometry analysis for sIgM fluorescence inten- 
sity and for liposome binding are compared in Fig. 2. Shapes of the distribution 
curves for sIgM and for the direct binding of fluorescent liposomes are virtually 
indistinguishable. The sIgM concentration thus affects iiposome binding intensity 
on a per-cell basis to the same degree as observed for the total population. 
Solid-phase Competition Immunoassay.  Polyacrylamide beads with CH12  IgM 
attached were  used  to  measure  inhibition of the  CH12/DPSC  interaction by 
pure  compounds.  Beads  bearing  CH10  IgM  served  as  controls.  Addition of 
DSPC/DSPG/cholesterol liposomes loaded with sulforhodamine B  (-25  nmoi 
inorganic phosphate, 0.717 absorbance units at 565 nm) led to 55.5% liposome 
binding to CH12 solid-phase in 5  min. The CH10 solid phase bound <10%  of 
the total encapsulated dye. 
This absorbance assay was then used to test inhibition of the CH 12/liposome 
interaction by pure compounds. Binding of the dye-loaded tracer vesicles could IO0 
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FTGURr: 3.  Inhibition of binding of sulforhodamine B-loaded liposomes to solid-phase CH 12 
lgM.  Polyacrylamide beads coated with CH12  lgM  were incubated with  liposomes in  the 
presence of the indicated concentrations of inhibitors. (I-1), DSPC; (O),  sphingomyelin; (I), 
DSPG.  Liposome binding was determined spectrophotometrically, and is  expressed as  the 
percentage of the value observed in the absence of any added inhibitor. 
be inhibited  specifically by addition  of aqueous dispersions of either  DSPC or 
sphingomyelin  (which  share  only the  phosphatidylcholine  moiety),  but  not by 
DSPG.  Competition  curves  were  generated  and  are  shown  in  Fig.  3.  The 
apparently  higher avidity of the CH12  IgM for sphingomyelin  than  for DSPC 
may be due either to vesicle structure (sphingomyelin may form fewer multilam- 
melar vesicles and hence present greater membrane surface per unit weight), or 
to alternative conformation of the polar head groups in the two compounds. In 
any event, it is clear that the phosphatidyl choline moiety is the epitope recognized 
by CH12. 
Discussion 
Six  of the  CH  series  of B  cell  lymphomas  bear  surface  Ig  that  recognize 
determinants on both SRBC and BrMRBC (3). We have shown here that the CH 
lymphomas  with  this  erythrocyte  specificity  also  recognize  the  phosphatidyl 
choline moiety in synthetic liposome membranes. In addition to these six tumors, 
the CH series also includes five lymphomas whose cells form rosettes with E. coli, 
but not with erythrocytes, and three that react with BrMRBC but not with SRBC 
(5).  Although  none of these eight  tumors binds our indicator  liposomes,  their 
surface Ig are  idiotypically related  to  those  that  do.  Furthermore,  one of the 
tumors  that  has  now  been  shown  to  bind  phosphatidyl  choline  (CH34)  also 
crossreacts  with  E.  coli.  These  data  imply  that  there  is  a  structural  similarity 
between the various epitopes recognized by this group of B cells. 
We have noted that, although all SRBC/phosphatidyl choline-specific tumors 
also bind BrMRBC, there are three CH lymphomas with specificity for BrMRBC 
only, and  these  tumors  do not  bind  DSPC-containing  iiposomes.  This  implies 
that  BrMRBC carry two different cell surface epitopes that  are recognized by 
different tumors,  but which  might  be expected to be chemically related  struc- 
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Based on the observation that the CH lymphomas display a restricted repertoire 
of idiotopes and antigen-binding specificities, Pennell et al.  (5),  concluded that 
these tumors derived from a  subset of B  cells defined by the expression of a 
limited number of V. gene products. Bishop and Haughton (6) found that the 
idiotype of one of these tumors, CH 12, is also expressed by a high proportion of 
normal 2a4  b spleen cells, which form spontaneous plaques with both SRBC and 
BrMRBC. We have now shown that the Ig of CH12 and five other iymphomas 
with  specificity for  SRBC  and  BrMRBC  recognize  the  phosphatidyl  choline 
epitope.  Although less  than  formal proof,  these observations strongly suggest 
that binding of the Ig to erythrocytes involves the phosphatidyl choline groups 
associated with membrane iipids. We propose that this is the basis for spontaneous 
plaque formation by normal splenic B cells. Further substantiation is also given 
to the conclusion that the CH lymphomas are derived from a subset of B cells, 
the normal counterpart of which includes the spontaneous plaque-forming cells. 
Lord and  Dutton  (13)  suggested that  the spontaneous plaque-forming cells 
found in normal spleens are representative of an autoimmune response against 
antigenic  determinants  to  which  the  animal  is  continuously  exposed.  They 
suggested that  the determinant recognized on  BrMRBC  becomes exposed in 
vivo on effete erythrocytes, providing a means for their recognition and elimi- 
nation. More recently, Grabar (14) has suggested that antibodies' protective role 
as defenders against microbial invasion may have evolved from a more ancient 
physiological function as transport molecules and in internal homeostasis. Based 
on the high incidence of naturally occurring antibodies to liposomes and phos- 
pholipids  in  normal  human  sera,  Alving  (15)  also  proposed  a  physiological 
function for these autoantibodies. Hayakawa et al. (16), have recently shown that 
Ly-1 + B cells have a  lineage distinct from the majority of other B  cells.  This 
group had previously proposed that Ly-1 ÷ B cells are responsible for the produc- 
tion  of several commonly studied  IgM  autoantibodies (4).  They showed that 
FACS-sorted IgM  +, Ly-1 ÷ cells from young NZB mice synthesized essentially all 
of the  IgM  anti-DNA  antibodies  seen  in  in  vitro  splenic cultures from these 
animals. FACS-sorted Ly-1 + B cells from BALB/c mice contained the subpopu- 
lation which, upon LPS stimulation, formed hemolytic plaques with BrMRBC. 
Given that the SRBC/DSPC-specific CH lymphomas all express the Ly-1 surface 
marker (5), our data suggest a relationship between the spontaneous antierythro- 
cyte and anti-DNA specificities. Precedent for such a claim can be inferred from 
a recent report from Diamond and Scharff (17). From cultures of the phosphoryl 
choline-binding myeloma S107,  a  variant was selected that  makes an  Ig with 
only a single amino acid difference from the parental line, resulting in a loss of 
phosphoryl choline binding and an acquired reactivity with DNA. 
There are also several well-known antibody crossreactivities resulting from the 
similarity in  chemical structure between phospholipid  membranes and the re- 
peating phosphodiester linkages found in nucleic acids. The classic  example of 
such crossreactivity is the false VDRL-positives due to the recognition of cardi- 
olipin by anti-DNA antibodies present in  the sera of SLE patients (18).  Some 
SLE sera are also known to have anticoagulant activity residing in the Ig fraction, 
which is crossreactive with antiphospholipid and anti-DNA antibodies (19). Lafer 
et al.  (28),  produced hybridomas from spleens of unimmunized MRL/1  mice MERCOLINO ET  AL.  163 
(which spontaneously develop severe SLE).  Using competitive RIA, they were 
able  to  demonstrate  that  a  variety of phospholipids  would  block  binding  of 
hybridoma antibodies to denatured DNA. One antibody prolonged the partial 
thromboplastin time, as is characteristic of lupus anticoagulant, and this activity 
could be blocked by cardiolipin. They concluded that a range of abnormalities 
seen in SLE could result from binding of certain autoantibodies to biologically 
ubiquitous phosphodiester-containing epitopes. 
In humans, tumors of B cell chronic lymphocytic leukemias (B-CLL) present 
phenotypic characteristics (reviewed in 21) that are strikingly similar to those of 
the CH series of murine lymphomas. Typical of B-CLL is the expression of the 
Leu- 1/T 1 surface marker, the human homolog of Ly- 1 (2). In concordance with 
this  observation  is  the  frequent  preceding  or  concomitant  manifestation  of 
autoimmune phenomena in association with B-CLL. Most notably, ~20% of B- 
CLL patients  develop autoimmune hemolytic anemia (21),  consistent with an 
antiphospholipid specificity of the mAb produced by the tumor. We are aware 
of at least one reported case of a  B-CLL producing an IgM crossreactive with 
cardiolipin,  phosphatidyl choline and  several other phospholipids  (22).  Other 
human B-CLL are likely to  share this  antigen specificity; rosettes with SRBC 
have been reported to be formed by leukemic B cells via their cell surface Ig 
(17). The normal Leu-1/T 1  + B cell precursors of B-CLL may play a role in other 
autoimmune diseases,  as  has  been  suggested for the murine  Ly-I ÷ subset  by 
Hayakawa et al., (4). Caligaris-Cappio and Janossy (21) recently proposed such a 
role  for  these  Leu-1/T1  cells  in  human  SLE.  The  question  remains  to  be 
answered whether reactivity for phosphorylated autoantigens is characteristic of 
malignant B cells, or, as seems more likely, is a  feature shared by normal and 
aberrant Ly-1 + (Leu-1/T1 +) B cells. The use of fluorescent iiposomes promises 
to be a powerful technique for addressing this question. 
Summary 
Cells from 6 of 14 different Ly-1 ÷ murine B cell lymphomas bound to synthetic 
liposomes encapsulating fluorescein. The liposomes were made from distearoyl 
phosphatidyl choline (DSPC), distearoyl phosphatidyl glycerol (DSPG), and cho- 
lesterol. In all cases, liposome binding was due to recognition of phosphatidyl 
choline by  the  surface  IgM  on  the  tumor  cells.  Liposome binding  could be 
inhibited by DSPC but not by DSPG, and the number of liposomes bound per 
cell  was  directly related  to  the  cell  surface concentration of IgM.  The  IgM 
secreted by a hybridoma derived from one of the lymphomas, CH 12, was shown 
to agglutinate liposomes, and was used in a  solid-phase immunoassay to study 
inhibition of iiposome binding by pure phospholipids; DSPC and sphingomyelin 
both inhibited, whereas DSPG did not. 
The Ig borne by the six lymphomas that bind phosphatidylcholine also bind 
to both SRBC and bromelain-treated mouse erythrocytes. The idiotypic of CH 12 
IgM  is  similar to  that expressed by  Ly-1 + normal splenic  B cells of the same 
specificity. The significance of these data in relation to other commonly studied 
autoantigens, and to the restricted specificity of normal Ly-1 ÷ B cells is discussed. 
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reading of the manuscript. 
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